These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation. Zuco V; Pasquali S; Tortoreto M; Brich S; Percio S; Dagrada GP; Colombo C; Sanfilippo R; Lauricella C; Gounder M; El Bezawy R; Barisella M; Dei Tos AP; Casali PG; Gronchi A; Stacchiotti S; Zaffaroni N J Exp Clin Cancer Res; 2021 Mar; 40(1):83. PubMed ID: 33648535 [TBL] [Abstract][Full Text] [Related]
5. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma. Bill KL; Garnett J; Meaux I; Ma X; Creighton CJ; Bolshakov S; Barriere C; Debussche L; Lazar AJ; Prudner BC; Casadei L; Braggio D; Lopez G; Zewdu A; Bid H; Lev D; Pollock RE Clin Cancer Res; 2016 Mar; 22(5):1150-60. PubMed ID: 26475335 [TBL] [Abstract][Full Text] [Related]
6. Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models. Li H; Wozniak A; Sciot R; Cornillie J; Wellens J; Van Looy T; Vanleeuw U; Stas M; Hompes D; Debiec-Rychter M; Schöffski P Transl Oncol; 2014 Dec; 7(6):665-71. PubMed ID: 25500074 [TBL] [Abstract][Full Text] [Related]
7. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models. Hao X; Bahia RK; Cseh O; Bozek DA; Blake S; Rinnenthal J; Weyer-Czernilofsky U; Rudolph D; Artee Luchman H Neuro Oncol; 2023 May; 25(5):913-926. PubMed ID: 36521007 [TBL] [Abstract][Full Text] [Related]
8. Establishment and characterization of NCC-DDLPS3-C1: a novel patient-derived cell line of dedifferentiated liposarcoma. Tsuchiya R; Yoshimatsu Y; Noguchi R; Ono T; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T Hum Cell; 2021 May; 34(3):1008-1018. PubMed ID: 33677797 [TBL] [Abstract][Full Text] [Related]
9. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas. Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371 [TBL] [Abstract][Full Text] [Related]
10. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas? Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499 [TBL] [Abstract][Full Text] [Related]
11. MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action. Somaiah N; Tap W Cancer Treat Rev; 2024 Jan; 122():102668. PubMed ID: 38104352 [TBL] [Abstract][Full Text] [Related]
12. Detection of Rekhi B; Karnik N; Agrawal R; Shetty O; Patkar S Indian J Pathol Microbiol; 2022; 65(1):65-75. PubMed ID: 35074968 [TBL] [Abstract][Full Text] [Related]
13. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Peng T; Zhang P; Liu J; Nguyen T; Bolshakov S; Belousov R; Young ED; Wang X; Brewer K; López-Terrada DH; Oliveira AM; Lazar AJ; Lev D Lab Invest; 2011 Mar; 91(3):392-403. PubMed ID: 21060307 [TBL] [Abstract][Full Text] [Related]
14. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas. Italiano A; Bianchini L; Gjernes E; Keslair F; Ranchere-Vince D; Dumollard JM; Haudebourg J; Leroux A; Mainguené C; Terrier P; Chibon F; Coindre JM; Pedeutour F Clin Cancer Res; 2009 Sep; 15(18):5696-703. PubMed ID: 19737942 [TBL] [Abstract][Full Text] [Related]
15. Chromosome-12 copy number alterations and MDM2, CDK4 and TP53 expression in soft tissue liposarcoma. Segura-Sánchez J; González-Cámpora R; Pareja-Megia MJ; García-Escudero A; Galera-Ruiz H; López-Beltrán A Anticancer Res; 2006; 26(6C):4937-42. PubMed ID: 17214366 [TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of NCC-DDLPS1-C1: a novel patient-derived cell line of dedifferentiated liposarcoma. Tsuchiya R; Yoshimatsu Y; Noguchi R; Sei A; Takeshita F; Sugaya J; Fukushima S; Yoshida A; Ohtori S; Kawai A; Kondo T Hum Cell; 2021 Jan; 34(1):260-270. PubMed ID: 32949334 [TBL] [Abstract][Full Text] [Related]